Evidence map›Paper›PMID 31100478›Full record

ArticleFree radical biology & medicine2019

p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.

Dannah R Miller, Matthew A Ingersoll, Arpita Chatterjee, Brian Baker, Shashank Shrishrimal, Elizabeth A Kosmacek, Yuxiang Zhu, Pi-Wan Cheng, Rebecca E Oberley-Deegan, Ming-Fong Lin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Free radical biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Dannah R MillerDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Matthew A IngersollDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Arpita ChatterjeeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Brian BakerDepartment of Biology, Clark Atlanta University, Atlanta, GA, USA.
Shashank ShrishrimalDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Elizabeth A KosmacekDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Yuxiang ZhuDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Pi-Wan ChengDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Rebecca E Oberley-DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Ming-Fong LinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Section of Urology, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: mlin@unmc.edu.
University of Nebraska Medical Center · USClark Atlanta University · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Nebraska Center for Nanomedicine- Pilot ProjectsP30GM127200 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2018 to 2022
$5.7M
SIGNALING IN ANDROGEN REFRACTORY PROSTATE CANCERR01CA088184 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LIN, MING-FONG · 2000 to 2010
$2.6M
MnTE-2-PyP as a radioprotector in prostate cancer therapyR01CA178888 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OBERLEY-DEEGAN, REBECCA E · 2014 to 2018
$1.6M
Cadherin-catenin Complex and YAP1 in Prostate CancerR03CA230950 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LIN, MING-FONG · 2018 to 2019
$153k
NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA088184NCI NIH HHS R01 CA178888NCI NIH HHS R03 CA230950NCI NIH HHS T32 CA009476NIGMS NIH HHS P30 GM127200
6 · The paper itself

Abstract

Prostate cancer (PCa) remains the second leading cause of cancer-related deaths in U.S. men due to the development of the castration-resistant (CR) PCa phenotype. A useful cell model for analysis of the molecular mechanism of PCa progression is required for developing targeted therapies toward CR PCa. In this study, we established a PCa cell progressive model in three separate cell lines, of which androgen-independent (AI) cells were derived from respective androgen-sensitive (AS) cells. Those AI PCa cells obtain the biochemical properties of the clinical CR phenotype, including AR and PSA expression as well as enhanced proliferation and tumorigenicity under androgen-deprived conditions. Thus, those AI cells recapitulate CR PCa and exhibit increased oxidant species levels as well as enhanced signaling of proliferation and survival pathways. H

Indexed as

Gene Expression Regulation, NeoplasticAcetylcysteineAnimalsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDrug Resistance, NeoplasmGene Expression ProfilingHeterograftsHumansHydrogen PeroxideKallikreinsLymphatic MetastasisMaleAcetylcysteineAntineoplastic AgentsHydrogen PeroxideKallikreinsKLK3 protein, humanProstate-Specific AntigenReactive Oxygen SpeciesReceptors, AndrogenSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1Castration-resistant prostate cancerp66ShcProstate cancerROS

Identifiers

PMID31100478
PMCPMC6620027
OpenAlexW2945443738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.